MedTrace Logo

Treatment of Systemic Sclerosis With Autologous Regulatory Т-cells

NCT05214014 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-09-14

No results posted yet for this study

Summary

Treatment of patients with systemic sclerosis with autologous regulatory Т-cells

Conditions

Interventions

BIOLOGICAL

Autologous Regulatory Т-cells

Autologous Regulatory Т-cells obtained from CD4+CD25+ cells isolated from PBMC and cultured with the cocktail of cytokines and antibodies to induce proliferation of Tregs

OTHER

Standard treatment according to the clinical protocols

Standard treatment of Systemic Sclerosis according to the clinical protocols

Sponsors & Collaborators

  • Belarusian State Medical University

    collaborator OTHER

  • Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus

    lead OTHER_GOV

Principal Investigators

  • Andrei Hancharou, Dr · the Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus

  • Kanstantsin Chyzh, Dr · Belarusian State Medical University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-01
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • Belarus

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05214014 on ClinicalTrials.gov